EGFR-mutant NSCLC exhibited distinctive TME features in PD-L1 expression, tumor mutation burden (TMB), and CD8+ tumor infiltration lymphocytes (TILs) compared with wild type NSCLC [7]. The gene discussed is CD8A; the disease is neoplasm.